Intervention

Pioglitazone 45 mg

ClinicalTrials.gov intervention label

Clinical trials7

Recruiting1

Common conditions9

Lead sponsors shown6

Clinical trials

7 shown

Adipose Tissue Heterogeneity and Its Link to Type 2 DiabetesNCT05501483 · 2023-02-08

Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?NCT06922656 · 2025-09-15

NOT_YET_RECRUITING

The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and CachexiaNCT05919147 · 2024-01-03

ACTIVE_NOT_RECRUITING

Effect of Pioglitazone on T2DM Patients With COVID-19NCT04604223 · 2021-01-18

Pioglitazone Treatment for Hyperglycemic Acute Ischemic StrokeNCT04123067 · 2020-09-01

Dapagliflozin Plus Pioglitazone in T1DMNCT03878459 · 2019-08-08

ACTIVE_NOT_RECRUITING

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 WeeksNCT01183013 · 2010-08-01

Common conditions

Type 2 Diabetes2 Covid191 Diabetes1 Diabetes Mellitus, Type 21 Hyperglycemia1 Lung Cancer1 Stroke, Acute1 Type 1 Diabetes1 Type 1 Diabetes Mellitus1

Leading sponsors

Dasman Diabetes Institute2 Boehringer Ingelheim1 Karolinska Institutet1 Milton S. Hershey Medical Center1 Pennington Biomedical Research Center1 The University of Texas Health Science Center at San Antonio1

Trial status mix

ACTIVE_NOT_RECRUITING2

COMPLETED1

NOT_YET_RECRUITING1

RECRUITING1

TERMINATED1

UNKNOWN1

Phase mix

PHASE43

PHASE22

NA1

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.